News & Updates

New research suggests that metabolic health, not just weight, plays a significant role in the development of obesity-related cancers in postmenopausal women.

Adherence to a healthy dietary pattern can help reduce the risk of all cancers, suggests a study.

Oral arsenic trioxide (ATO) for the treatment of acute promyelocytic leukaemia (APL), developed at the Li Ka Shing Faculty of Medicine at the University of Hong Kong (HKU), is the first-ever prescription medication wholly invented and manufactured in Hong Kong to obtain US, European and Japanese patents, and the first to receive orphan drug designation (ODD) from US FDA and the European Medicines Agency (EMA) as well as an investigational new drug designation (IND) from the US FDA. According to APL Asian Consortium’s (APLAC) data collected over a 21.5-year period, frontline oral or intravenous (IV) ATO significantly decreases early deaths and improves relapse-free survival (RFS) and overall survival (OS) vs ATO-free regimens.

Some cancer patients with acute oncology-related presentations at the emergency department (ED) can be managed at ambulatory clinics, suggests a Singapore study.

A contact X-ray brachytherapy (CXB) dose escalation enhances the organ preservation (OP) rate of patients with early rectal adenocarcinoma, with good bowel function at 3 years, results of the OPERA trial have shown. This benefit persists at year 5, particularly in those with small early-stage tumours.